Description  Claims  Drawing  Cited references 

WO2006095783A   [0015]  [0045] 
WO2009023211A   [0015] 
WO2007134678A   [0015] 
JP2012500013A   [0015] 
WO2011060328A   [0015] 
WO2013009655A2   [0015] 
WO2010020618A1   [0015] 
WO2006109085A1   [0015] 
WO2007139952A   [0045] 

Activity of a Specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome   [0016] 
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib   [0016] 
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study   [0016] 
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2   [0016] 
Lapatinib plus capecitabine for HER2-positive advanced breast cancer   [0016] 
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer   [0016] 
Hsp90 inhibitors as novel cancer chemotherapeutic agents   [0016] 
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging   [0016] 
Targeting the Raf-MEK-ERK mitogen-actiated protein kinase cascade for the treatment of cancer   [0016] 
Activity of the Heat Shock Protein 90 Inhibitor Genetespb in Melanoma   [0016] 
Targeting KRAS-Mutant Non-Small Lung Cell Cancer with the HSP90 Inhibitor Ganetespib   [0016]